December 15, 2011 11:14 AM EST
UBS initiates coverage on Hospira (NYSE: HSP) with a Sell. PT $25.00.
UBS analyst says, "HSP looks attractive at its current 52-week low levels, given its strong medium/long-term growth prospects. But we think it is too early to build a position in the name, as consensus for 2012/2013 seems still high and manufacturing issues will probably worsen before improving. We plan to revisit our view in 2012 as we gain visibility into EPS growth...We are $0.35-0.40 below consensus for both years as we believe recovery from manufacturing issues could be slow and management will invest in R&D in line with its previous guidance."
For an analyst ratings summary and ratings history on Hospira click here. For more ratings news on Hospira click here.
Shares of Hospira closed at $28.21 yesterday, with a 52 week range of $26.92-$59.20.
http://www.streetinsider.com/New+Co...to+Get+Involved,+But+Still+Early/7023125.html
UBS initiates coverage on Hospira (NYSE: HSP) with a Sell. PT $25.00.
UBS analyst says, "HSP looks attractive at its current 52-week low levels, given its strong medium/long-term growth prospects. But we think it is too early to build a position in the name, as consensus for 2012/2013 seems still high and manufacturing issues will probably worsen before improving. We plan to revisit our view in 2012 as we gain visibility into EPS growth...We are $0.35-0.40 below consensus for both years as we believe recovery from manufacturing issues could be slow and management will invest in R&D in line with its previous guidance."
For an analyst ratings summary and ratings history on Hospira click here. For more ratings news on Hospira click here.
Shares of Hospira closed at $28.21 yesterday, with a 52 week range of $26.92-$59.20.
http://www.streetinsider.com/New+Co...to+Get+Involved,+But+Still+Early/7023125.html